RTP Mobile Logo

Wednesday, December 11, 2019, San Antonio, Texas, 7:30 PM – 9:00 PM

Data + Perspectives: Clinical Investigators Explore the Current and Future Management of ER-Positive Breast Cancer

Part 1 of a 3-Part CME Satellite Symposia Series

Event Details

San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

7:30 PM – 9:00 PM — Educational Dinner Meeting

Meeting Room
Grand Ballroom G-M (Third Floor)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Harold J Burstein, MD, PhD
Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew Goetz, MD
Professor of Oncology and Pharmacology
Mayo Clinic
Rochester, Minnesota

Stephen RD Johnston, MA, PhD
Professor of Breast Cancer Medicine and
Head of Medical Oncology
Consultant Medical Oncologist and
Head of the Breast Unit
The Royal Marsden NHS Foundation Trust and
The Institute of Cancer Research
Chelsea, London, United Kingdom

Joseph A Sparano, MD
Associate Chairman, Department of Oncology
Montefiore Medical Center
Associate Director for Clinical Research
Albert Einstein Cancer Center
Albert Einstein College of Medicine
Bronx, New York

Neil Love, MD
Research To Practice
Miami, Florida


MODULE 1: Use of Genomic Classifiers to Inform Therapeutic Decision-Making for Patients with ER-Positive Localized Breast Cancer (BC)

  • Impact, if any, of age, grade and other clinicopathologic factors on the decision to consult a genomic classifier in the adjuvant setting
  • Design, eligibility criteria, primary and secondary endpoints and major clinical findings from the Phase III TAILORx intermediate-risk cohort
  • Implications of the TAILORx intermediate-risk cohort results for adjuvant treatment for pre- and postmenopausal patients with localized BC
  • Value of classic clinical features to complement 21-gene Recurrence Score® findings in various patient subsets; indications for routine practice
  • Available data with and current clinical role of genomic classifiers in patients with node-positive disease
  • Investigator perspectives on the current utility of other genomic assays beyond the 21-gene Recurrence Score assay in node-negative or node-positive, ER-positive localized BC

MODULE 2: Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive Metastatic BC (mBC)

  • Clinical factors affecting the use and selection of CDK4/6 inhibitors with endocrine therapy as first-line treatment for ER-positive mBC (eg, prior endocrine therapy, symptomatology, performance status, disease-free interval, sites of metastases)
  • Long-term follow-up data, including overall survival findings, with and current clinical role of CDK4/6 inhibitors in premenopausal and postmenopausal patients
  • Comparative CNS activity of commercially available CDK4/6 inhibitors and implications, if any, for the care of patients with ER-positive brain metastases
  • Potential molecular biomarkers of response to CDK4/6 inhibition
  • Recent FDA announcement of possible severe lung inflammation associated with CDK4/6 inhibitors; monitoring for and management of this and other toxicities in patients receiving these agents
  • Role of CDK4/6 inhibition in elderly patients with ER-positive mBC; unique administration, monitoring and/or toxicity management considerations

MODULE 3: Current and Future Management of ER-Positive mBC After Disease Progression on CDK4/6 Inhibition

  • Role of the PI3K/AKT/mTOR signaling pathway in BC formation and progression
  • Proposed mechanisms of resistance to CDK4/6 inhibition and selection of therapy for individuals experiencing disease progression on these agents; current clinical role of everolimus/exemestane or everolimus/fulvestrant for this population
  • Incidence, identification and prognostic significance of PI3K mutations in patients with ER-positive mBC
  • Design, eligibility criteria and key efficacy data from the Phase III SOLAR-1 trial evaluating alpelisib/fulvestrant versus fulvestrant alone for patients with a PIK3CA mutation after disease progression on first-line endocrine therapy; FDA approval and current clinical role
  • Spectrum, frequency and severity of toxicities observed with alpelisib in SOLAR-1; optimal approaches to side-effect management
  • Ongoing investigation of other strategies designed to exploit the PI3K/AKT/mTOR pathway (eg, gedatolisib, ipatasertib, capivasertib)
  • Biologic rationale for the evaluation of Bcl-2 inhibition for patients with ER-positive mBC; available data and ongoing trials with venetoclax

MODULE 4: Novel Applications of CDK4/6 Inhibitors; Ongoing Clinical Trials

  • Early activity and safety data with the use of CDK4/6 inhibitors as neoadjuvant therapy; ongoing evaluation and potential clinical role
  • Design of, entry criteria for and similarities and differences between ongoing randomized Phase III trials exploring the potential role of adjuvant CDK4/6 inhibition in combination with endocrine therapy
  • Recently reported results from the Phase II monarcHER trial evaluating the contribution of abemaciclib to trastuzumab with and without fulvestrant for patients with ER-positive, HER2-positive locally advanced or metastatic BC
  • Potential role of abemaciclib in combination with trastuzumab and fulvestrant for patients with ER-positive, HER2-positive mBC
  • Biologic rationale for, early research experience with and ongoing evaluation of CDK4/6 inhibitors in combination with other systemic therapies (agents targeting the mTOR/PI3K/AKT pathway, immune checkpoint inhibitors, et cetera)

CE Information

Target Audience
This activity is intended for medical oncologists, breast cancer surgeons, radiation oncologists and other healthcare professionals involved in the diagnosis and treatment of breast cancer.

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Consider published research data, consensus-based guidelines and other peer-reviewed sources to inform the use of biomarkers and genomic classifiers to assess risk and customize therapy for patients with localized hormone receptor-positive breast cancer.
  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed ER-positive metastatic breast cancer (mBC), considering clinical presentation (eg, age, menopausal status, comorbidities, extent and sites of disease), prior treatment course (eg, de novo metastatic disease, type and duration of adjuvant therapy) and psychosocial status.
  • Appreciate the means by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and recognize how the inhibition of CDK4/6 has improved outcomes for patients with ER-positive metastatic disease.
  • Recall the FDA indications for the commercially available CDK4/6 inhibitors, and discern how these agents can be optimally employed in the nonresearch care of patients with ER-positive mBC.
  • Develop an optimal approach to local and systemic therapy for patients with ER-positive breast cancer and CNS metastases, considering the implications of symptomatology, number of lesions and other relevant factors.
  • Appraise available research data and clinical investigators’ perspectives to formulate appropriate clinical recommendations for patients who experience disease progression on CDK4/6 inhibitors in combination with hormonal therapy.
  • Recognize the frequency of phosphoinositide-3 kinase (PI3K) pathway mutations in patients with ER-positive mBC, and assess published research data with the use of novel agents targeting these abnormalities.
  • Understand the side effects associated with existing and recently approved systemic therapies for ER-positive breast cancer, and develop strategies to prevent or ameliorate toxicities to support quality of life and continuation of treatment.
  • Assess ongoing clinical research studies evaluating novel agents and treatment strategies under development for ER-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genomic Health Inc, Lilly and Novartis.


San Antonio Marriott Rivercenter
101 Bowie Street
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom G-M (Third Floor)

The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center.



Thank you for your interest in our CME program. At this time online preregistration is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. If you are interested in attending, please visit our onsite registration desk, which will open at 7:00 PM on Wednesday, December 11. Our onsite registration desk will be located outside Grand Ballroom G-M on the third floor of the Marriott Rivercenter hotel (101 Bowie Street, San Antonio, TX 78205), which is within 1.5 blocks of the Henry B González Convention Center. 

We will accept onsite registration until reaching the meeting room capacity. Please note, onsite registration does not guarantee participation in the session or meal service, and seating will be prioritized for clinicians in practice.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153 or +1 (305) 377-2828.


This educational session has been approved by SABCS as an official adjunct CME satellite symposium, and registration for this event is independent of registration for SABCS.